New Grip Technology™ Sealant Redefines Active Closure

 

Mountain View, CA (February 27, 2012) – AccessClosure, Inc., the market leader in extravascular closure devices, announced today the FDA approval and US launch of the MynxGrip Vascular Closure Device (VCD). Built on the proven Mynx platform, the MynxGrip VCD offers an active, extravascular and patient-friendly vascular closure solution. MynxGrip adds the proprietary Grip Technology sealant to the distal end of the original Mynx Sealant.

AccessClosure, Inc. Marches to the Millionth Mynx!

Mountain View, California (September 28, 2011) – Mountain View, California (May 17, 2011) - AccessClosure, Inc., a leading manufacturer of extravascular closure devices, announced today the shipment of its one millionth Mynx unit. The Mynx Vascular Closure Device received its FDA approval in May 2007, following with its full commercial launch in September 2007. Physician feedback attributes the achievement of this monumental milestone to the fact that the Mynx sealant is extravascular, bio-inert and non-thrombogenic, while leaving nothing behind intra-arterially.

Growth of Mynx Device Continues in International Markets

Mountain View, California (May 17, 2011) – Mountain View, California (May 17, 2011)- AccessClosure, Inc., the market segment leader in extravascular closure devices, announced today an exclusive agreement with Biosensors International for the distribution of the Mynx™ Vascular Closure Device throughout the United Kingdom, Switzerland and France. The extravascular Mynx device, designed for patient comfort while providing hemostasis without sutures or implants, will be sold as part of Biosensors’ interventional cardiology product range.

Study Results Support Improved Patient Comfort with the Mynx Device

Mountain View, California (March 3, 2011) – AccessClosure, Inc., the U.S. market segment leader in extravascular closure devices, announced today results from the first published study* (Journal of NeuroInterventional Surgery) comparing the pain associated with deployment of different vascular closure devices (VCD) as the primary endpoint.

Enhanced Device Offers a Marked Advancement in Closure

Mountain View, California (January 11, 2011) – AccessClosure, Inc., the U.S. market leader in extravascular closure devices, announced today the launch of its next generation product, the Mynx Cadence Vascular Closure Device (VCD). With its simpler design and improved ease‐of‐use, Mynx Cadence offers physicians smoother device deployment while maintaining all the benefits of the original Mynx.

Focused on Strategic Growth and Continued Commercial Leadership

Mountain View, California (June 4, 2010) ‐ AccessClosure, a market leader in vascular closure devices, announced a leadership transition through which the company’s President & CEO, Fred Khosravi has been appointed to the role of Chairman of the Board, and Gregory D. Casciaro has joined the company as President and CEO.

Mynx M5™ Offers Patients “Artery-Friendly” Closure Solution

Mountain View, Calif (June 22, 2009) – AccessClosure today announced the newest addition to the Mynx® Vascular Closure family, the Mynx M5. The M5 is now the only closure device on the market that can be delivered directly through a small 5 French (5F) cardiovascular sheath without enlarging the arterial hole or traumatizing the surrounding tissue in the process. This “artery-friendly” approach also benefits hospitals as the M5 eliminates the need for a sheath exchange, which saves procedure time and expense.